Expanded FDA OTC inspection authority will ease global marketing -- FDAer.
This article was originally published in The Tan Sheet
LABEL PRINTING ERROR REDUCTION THROUGH GMPs should be priority for FDA and OTC drug manufacturers, FDA New Jersey District Director Douglas Ellsworth recommended at the Nonprescription Drug Manufacturers Association's annual small business seminar in East Rutherford, N.J. March 11-12. Noting that FDA has worked with industry for "a number of years" to reduce the amount of recalls related to mislabeling problems, such as the wrong label being attached to bottles, the FDAer said "we need to focus some of our efforts on the printing aspect -- what controls are necessary" to avoid misprints.
You may also be interested in...
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning